Administratiekantoor Westend Stichting

Participations S.A R.L. Artal (Director) sold 3,000,000 shares of CAVA at $90.30 for $270,900,000

Participations S.A R.L. Artal sold 3,000,000 shares representing -31.6% of pre-transaction holdings, reducing stakes from 9,507,990 shares to 6,507,990 shares. The sale occurred at $90.30 per share when current price stands at $88.05, near the 52-week high of $98.79 and well above the 52-week low of $43.41. Despite strong revenue growth of +22.4% year-over-year, the company trades at an elevated P/E of 166.13, which constrains near-term upside expectations. The director's substantial reduction in position size, combined with the high valuation multiple, provides context for the magnitude and timing of this divestiture.

Director Invus Global bought 1,538,462 shares (1.54M) of LXRX at $1.30 for $2,000,000.60 on 2026-02-02

Invus Global Management, LLC purchased 1,538,462 shares for $2,000,000.60 at $1.30 per share, a substantial discretionary acquisition by a director of Lexicon Pharmaceuticals. The transaction is notable given the company's operating profile: Lexicon generated $14,182,000.00 in latest quarterly revenue but reported a net loss of $-12,769,000.00 in the same period, and was unprofitable over its most recent full fiscal year. The stock currently trades at $1.27, slightly below the $1.30 purchase price. The 52-week range of $0.29–$1.76 places the transaction near the upper portion of recent historical trading, though the stock is -27.8% from its 52-week high. Investors should evaluate whether this director-level commitment reflects confidence in Lexicon's strategic direction or product pipeline, balanced against the sustained operating losses and modest revenue base.

Artal International (Director) sold 8,000,000 shares of CAVA at $134.13 for $1.1B, reducing stake from 17.51M to 9.51M shares (-45.7%).

Artal International executed a substantial $1,073,040,000.00 reduction of its CAVA position, selling 8,000,000 shares at $134.13 on 2024-11-18 and retaining 9,507,990 shares. This represents a 45.7% reduction in holdings. At the same-ticker level, Artal has conducted 4 prior sells at CAVA since February 2024, with outcomes ranging from -9.9% to +30.7% at the 30-day mark and -9.9% to +54.7% at the 90-day mark (0 of 3 measurable 90-day outcomes were well-timed for the seller). The current price of $139.69 stands 5.5% below the 52-week high of $147.80, and the stock has appreciated 37.0% over 90 days and 2.5% over 30 days—well above the transaction price. Fundamentals show an elevated P/E of 634.95 paired with strong 29.2% annual revenue growth. The magnitude and timing of this sale relative to price momentum and valuation context warrant close observation.

Artal International sells 6.00M CAVA shares at $116.36 (Aug 26), reducing stake to 17.51M; stock rallied +43.6% in 30 days post-sale.

Artal International, a director of CAVA Group, sold 6,000,000 shares at $116.36 on 2024-08-26, a -25.5% reduction of holdings to 17.51M shares, with total transaction value of $698,160,000.00. The stock has subsequently appreciated to $118.44 (current price), with a 30-day return of +43.6% post-transaction, indicating the sale preceded a material rally. Reviewing his same-ticker history at CAVA, prior sales on 2024-06-05, 2024-03-21, and 2024-02-27 posted 30-day returns of +8.9%, -9.9%, and +30.7% respectively, with a 90-day well-timed rate of 0 of 2 measurable sells—suggesting a pattern of selling into strength rather than ahead of declines. Against a 30-day backdrop of +43.6% post-sale appreciation and CAVA's trailing metrics (P/E 538.36, +29.2% revenue growth), the decision to reduce a substantial position warrants scrutiny of whether forthcoming results or conditions might justify such liquidation.